Nektar’s rezpegaldesleukin advances; BTIG reiterates Buy
TradingView News weekly recap says Nektar Therapeutics is progressing rezpegaldesleukin with positive Phase 2 data in atopic dermatitis and alopecia areata and multiple Phase 3 starts, and that BTIG reaffirmed a Buy rating and $178 price target.